BioCentury | Nov 15, 2019
Product Development

Lupus makes leaps with three good pieces of news

...reported last week at the American College of Rheumatology (ACR) / Association for Rheumatology Professionals (ARP...
...and III readouts at the American College of Rheumatology (ACR) / Association of Rheumatology Professionals (ARP...
BioCentury | Nov 13, 2019
Clinical News

Three late-stage wins shift the clinical landscape in SLE

...60 years. At the 2019 American College of Rheumatology (ACR) / Association for Rheumatology Professionals (ARP...
BioCentury | Aug 1, 2019
Distillery Therapeutics

Stabilizing the closed form of RyR2 for nephrotic syndrome

...phosphorylation were elevated in mice with nephrotic syndrome. In primary podocytes from the mice, recombinant MANF...
...and improved kidney function in the model. TARGET/MARKER/PATHWAY: Ryanodine receptor 2 (RyR2); mesencephalic astrocyte-derived neurotrophic factor (MANF; ARP; ARMET...
...Chen, Washington University in St. Louis, St. Louis, Mo. email: ychen@dom.wustl.edu Hongjiang Li Washington University in St. Louis Mesencephalic astrocyte-derived neurotrophic factor (MANF) (ARP) (ARMET) Ryanodine...
BioCentury | Nov 16, 2018
Company News

CFIUS pilot launch marks steps into biotech territory

Biotech could soon be getting more attention from the Committee of Foreign Investment in the United States as the Treasury Department's CFIUS pilot program went into effect over the weekend. "Biotech is still relatively new...
BioCentury | Nov 13, 2018
Politics & Policy

CFIUS pilot launch marks steps into biotech territory

Biotech could soon be getting more attention from the Committee of Foreign Investment in the United States as the Treasury Department's CFIUS pilot program went into effect over the weekend. "Biotech is still relatively new...
BioCentury | Nov 10, 2017
Politics & Policy

Second Brady amendment removes potentially disruptive provision on non-qualified deferred compensation

A provision related to the tax treatment of non-qualified deferred compensation that could have caused a fundamental change in pay practices across the biotech industry was scrapped on Thursday. House Ways and Means Committee Chairman...
BioCentury | Oct 17, 2017
Distillery Therapeutics

Ophthalmic disease

...testing to treat diabetic macular edema (DME), diabetic retinopathy and macular edema. Aerpio also has ARP-1536...
BioCentury | Jul 21, 2016
Distillery Therapeutics

Therapeutics: Mesencephalic astrocyte-derived neurotrophic factor (MANF; ARP; ARMET)

...MANF expression. In a mouse model of UV light-induced retinal damage, intravitreal injection of human MANF...
...effects of MANF on brain damage and other damaged tissues. Amarantus BioScience Holdings Inc. has MANF...
...Inc. have MANF in preclinical testing for traumatic brain injury (TBI). TARGET/MARKER/PATHWAY: Mesencephalic astrocyte-derived neurotrophic factor (MANF; ARP; ARMET...
BioCentury | Sep 1, 2015
Company News

Amicus to acquire Scioderm

Amicus Therapeutics Inc. (NASDAQ:FOLD) will acquire Scioderm LLC (Raleigh, N.C.), giving it Zorblisa ( SD-101 ), an undisclosed topical cream to treat epidermolysis bullosa (EB). The company expects data in 1H16 from the Phase III SD-005...
BioCentury | Jun 5, 2015
Company News

Mindray management proposes taking company private

Chinese medical device company Mindray Medical International Ltd. (NYSE:MR) gained $3 (11%) to $30.47 on Thursday on news that three members of its management team proposed to take the company private for $30 per share....
Items per page:
1 - 10 of 73